Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maximilian Merz

Showing results (121-130 of 127) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 127 results.
Cancer Cell|December 5, 2025
A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myelomaMichael Rade, David Fandrei, Markus Kreuz, et al.
Blood Cancer Journal|December 5, 2024
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapyMaximilian Merz, Danai Dima, Hamza Hashmi, et al.
Eclinicalmedicine|June 19, 2026
Fertility management and outcomes after CAR T-cell therapy: an international survey from the Cellular Therapy and Immunobiology working party of the European Society for Blood and Marrow TransplantationGiorgio Orofino, Isabel Sánchez-Ortega, Juana Schwartz Mota, et al.
Blood Cancer Discovery|June 12, 2026
Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple MyelomaMaximilian Merz, Tomas Jelinek, Thomas Pabst, et al.
Leukemia & Lymphoma|January 12, 2019
Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE studyDaniele Campa, Alessandro Martino, Angelica Macauda, et al.
NPJ Digital Medicine|August 1, 2025
Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapiesUlrike Weirauch, Markus Kreuz, Colin Birkenbihl, et al.
Blood|August 1, 2025
Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapyBinod Dhakal, Othman Salim Akhtar, David Fandrei, et al.
Pageof 13

Showing results (121-130 of 127) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 127 results.
Cancer Cell|December 5, 2025
A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myelomaMichael Rade, David Fandrei, Markus Kreuz, et al.
Blood Cancer Journal|December 5, 2024
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapyMaximilian Merz, Danai Dima, Hamza Hashmi, et al.
Eclinicalmedicine|June 19, 2026
Fertility management and outcomes after CAR T-cell therapy: an international survey from the Cellular Therapy and Immunobiology working party of the European Society for Blood and Marrow TransplantationGiorgio Orofino, Isabel Sánchez-Ortega, Juana Schwartz Mota, et al.
Blood Cancer Discovery|June 12, 2026
Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple MyelomaMaximilian Merz, Tomas Jelinek, Thomas Pabst, et al.
Leukemia & Lymphoma|January 12, 2019
Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE studyDaniele Campa, Alessandro Martino, Angelica Macauda, et al.
NPJ Digital Medicine|August 1, 2025
Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapiesUlrike Weirauch, Markus Kreuz, Colin Birkenbihl, et al.
Blood|August 1, 2025
Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapyBinod Dhakal, Othman Salim Akhtar, David Fandrei, et al.
Pageof 13